撤回"官宣"，公司回应 "官宣！复星联合健康保险9款医疗险覆盖商保创新药！"12月18日，北京商报记者了解到，复星联合健 康保险的一则公告在行业引起关注。 多天前，首版《商业健康保险创新药品目录》公布，目录中19种创新药被正式推向了商业健康保险的舞 台中央。业内正翘首以待，谁会将目录中的创新药纳入保险保障，成为第一批"吃螃蟹"的保险机构。一 则"官宣！复星联合健康保险9款医疗险覆盖商保创新药！"的推文便在保险圈炸开了锅。 然而，市场情绪的升温尚未持续太久，便出现了异样。12月18日，北京商报记者注意到，这篇承载着行 业期待的"官宣"文章，在其官方微信公众号上已然不见踪影，只留下"已删除"的提示。一场备受瞩目 的"官宣"，在众目睽睽之下上演了"撤回"的戏码。那么，从高调宣布到悄然撤回，这"虚晃一枪"的背 后，原因几何？对于整个健康险市场而言，首版商保创新药目录的发布，究竟意味着怎样的机遇与变 局？ "此前部分城市的惠民保宣传纳入商保创新药目录中的药，目前终于看到有保险公司官宣自家的中端医 疗险、长期医疗险纳入商保创新药目录中的药。"复星联合健康保险的官宣无疑令业内欣喜。 在中央财经大学副教授刘春生看来，将商保创 ...

Core Viewpoint - The announcement by Fosun United Health Insurance regarding the inclusion of nine medical insurance products covering commercial health insurance innovative drugs was retracted shortly after its release, raising questions about the internal decision-making process and the implications for the health insurance market [1][2][4]. Group 1: Announcement and Withdrawal - Fosun United Health Insurance initially announced that nine of its medical insurance products would cover innovative drugs listed in the newly released commercial health insurance innovative drug directory [1][3]. - The announcement was later deleted from their official WeChat account, with the company stating that the decision to retract was due to ongoing discussions and lack of finalization on the product details [2][3]. Group 2: Market Implications - The release of the commercial health insurance innovative drug directory, which includes 19 high-value innovative drugs, is seen as a potential opportunity to enhance the purchasing rate of commercial insurance [5]. - The inclusion of innovative drugs in medical insurance is viewed as a necessary direction for health insurance development, aiming to alleviate patients' financial burdens and improve product competitiveness [6]. Group 3: Financial Performance and Capitalization - Fosun United Health Insurance reported a net profit of 0.63 billion in the first three quarters of the year, continuing a trend of profitability since 2021 [7][8]. - The company has been seeking to increase its registered capital, with a recent approval to raise it from 6.9444 billion to 10.1085 billion, which is expected to enhance its capital strength and support the coverage of innovative drugs [9].